CN Patent

CN107249591A — 治疗癌症的方法

Assigned to Sanitary Material R&d Management Co ltd · Expires 2017-10-13 · 9y expired

What this patent protects

本发明涉及包含人类组蛋白甲基转移酶EZH2的一种或多种抑制剂的药物组合物，和使用这一种或多种EZH2抑制剂治疗癌症的方法。

USPTO Abstract

本发明涉及包含人类组蛋白甲基转移酶EZH2的一种或多种抑制剂的药物组合物，和使用这一种或多种EZH2抑制剂治疗癌症的方法。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN107249591A
Jurisdiction: CN
Classification: —
Expires: 2017-10-13
Drug substance claim: No
Drug product claim: No
Assignee: Sanitary Material R&d Management Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.